SRR10899980
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- MYC_TARGETS_V1+0.400
- PROTEIN_SECRETION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ANDROGEN_RESPONSE+0.300
- MTORC1_SIGNALING+0.300
- PANCREAS_BETA_CELLS+0.300
- ADIPOGENESIS+0.200
- HEDGEHOG_SIGNALING+0.200
- HYPOXIA+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- INFLAMMATORY_RESPONSE-0.300
- E2F_TARGETS-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- G2M_CHECKPOINT-0.200
- IL2_STAT5_SIGNALING-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A1EN-01A-11R-A13Q-07 | — | C | 0.809 |
| 2 | R148 | — | — | 0.785 |
| 3 | 56D3154E-E779-4C27-8305-FEE7310B6762 | — | — | 0.777 |
| 4 | 4ea93d27-97e3-40bd-8734-d026e48fbbe4 | — | — | 0.771 |
| 5 | BS_TBWYAFSM | EPN | EPN Tumor | 0.770 |
| 6 | BS_TBWYAFSM | Spinal Cord Ependymoma | — | 0.769 |
| 7 | 5085CE66-190D-478B-9AB6-55AE71C41CCF | — | — | 0.766 |
| 8 | MNG624 | — | — | 0.750 |
| 9 | MNG999 | — | — | 0.747 |
| 10 | BB79CABB-0912-4E02-ACD9-82EF3AB8B598 | — | — | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |